Examining which TARPs, if any, are predominantly expressed alongside AMPAR subunits in tumor cells may have therapeutic implications, as TARP-selective AMPAR antagonists are currently in clinical development [107,108,109,110,111,112,113,114]. This evidence concerns the gene RBM10 and neoplasm.